| |
6 months
|
12 months
|
Quality-adjusted survival at 12 months
|
|---|
| |
Mean EQ5D index (95 % CI)
|
Mean EQ5D index (95 % CI)
|
Mean QALY (95 % CI)
|
|---|
|
All patients
|
0.5622 (0.5163–0.6081)
|
0.5831 (0.5348–0.6314)
|
0.2676 (0.2457–0.2894)
|
|---|
|
Age
| | | |
|
<65
|
0.55 (0.49–0.60)
|
0.58 (0.53-0.64)
|
0.31 (0.28-0.35)
|
|
≥65
|
0.62 (0.52–0.71)
|
0.58 (0.48–0.68)
|
0.16 (0.12–0.21)
|
|
Gender
| | | |
|
Male
|
0.57 (0.51–0.63)
|
0.58 (0.52–0.64)
|
0.27 (0.23–0.30)
|
|
Female
|
0.55 (0.47–0.63)
|
0.59 (0.51–0.67)
|
0.27 (0.23–0.31)
|
|
APACHE II
| | | |
|
<26
|
0.57 (0.52–0.62)
|
0.57 (0.52–0.63)
|
0.29 (0.26–0.33)
|
|
≥26
|
0.48 (0.34–0.61)
|
0.60 (0.50–0.71)
|
0.16 (0.12–0.20)
|
|
PaO2:FiO2 ratio (KPa)
| | | |
|
<15
|
0.57 (0.51–0.64)
|
0.58 (0.51–0.65)
|
0.23 (0.20–0.27)
|
|
≥15
|
0.55 (0.48–0.63)
|
0.59 (0.52–0.65)
|
0.31 (0.27–0.35)
|
|
Ventilation method
| | | |
|
Conventional
|
0.52 (0.45–0.59)
|
0.55 (0.48–0.61)
|
0.25 (0.21–0.29)
|
|
HFOV
|
0.61 (0.54–0.67)
|
0.62 (0.55–0.69)
|
0.29 (0.25–0.33)
|
